



## GENFIT TO PRESENT AT THE PARIS SMALLCAP EVENT ON APRIL 12 & 13

**Lille (France), Cambridge (Massachusetts, United States), April 1<sup>st</sup>, 2010** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces its participation to the 5<sup>th</sup> edition of the Smallcap Event, on April 12 & 13, in Paris. The conference will take place at the Salons Hoche, 9 Avenue Hoche, 75008 Paris.

During the event, Laurent Lannoo, Corporate Secretary of GENFIT, and Rémy Hanf, Vice President Product Development, will meet fund managers to present financial results 2009, the latest pipeline breakthroughs and the strategic developments for 2010. GENFIT will be hosted at the Invest Securities stand.

### About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer's...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT's proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT's lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS (AVE0897) and SOLVAY (SLV341), are in the advanced stages of Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has about 120 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### Contacts:

#### GENFIT

Jean-François Mouney – Chairman of the Management Board  
+33 (0)3 20 16 40 00

#### MILESTONES – Press Relations

Bruno Arabian  
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – [barabian@milestones.fr](mailto:barabian@milestones.fr)

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.